Lyell Immunopharma, Inc. LYEL
Set alert
At close · Nov 2
After hours · Nov 2, 4:00 PM ET
- YTD
- -64.64%
- 1 year
- -34.67%
- Open
- 11.04
- Prev close
- 11.04
- Mkt cap
- 266.71M
- Vol
- 90.33K
- Avg vol
- 151.10K
- EPS
- -12.86
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 10.56
- High
- 11.29
- Forward P/E
- -0.73
- Beta
- -0.48
- Short ratio
- 6.15
- Inst. own
- 58.79%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 1.01
- 200-d avg
- 1.68
- 1y target
- 1.00
News
8 hours ago globenewswire.com
Lyell Immunopharma To Participate in November Investor Events
SOUTH SAN FRANCISCO, Calif., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor…
2 weeks ago zacks.com
Down 27% in 4 Weeks, Here's Why Lyell Immunopharma (LYEL) Looks Ripe for a Turnaround
Lyell Immunopharma (LYEL) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts…
1 month ago globenewswire.com
Lyell Immunopharma To Participate in the Baird 2026 Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Sept. 14, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation chimeric antigen…
-
1 month ago benzinga.com
Lyell Immunopharma Completes Transfer For LYL273 Candidate To LyFE Manufacture Center In Washington
Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor (CAR) T-cell therapies for patients with cancer, today…
1 month ago globenewswire.com
Lyell Immunopharma Completes Manufacturing Transfer for LYL273 and Provides Updated Timeline on Phase 1/2 Trial in Metastatic Colorectal Cancer
SOUTH SAN FRANCISCO, Calif., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation chimeric antigen…
2 months ago benzinga.com
This Lyell Immunopharma Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings…
2 months ago benzinga.com
This Lyell Immunopharma Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday
Wall Street analysts change outlook on top names. Check analyst ratings page for all changes. See what analysts say about LYEL, IMRX, and RNA.
2 months ago 247wallst.com
Here Are Thursday’s Top Wall Street Analyst Research Calls: AppLovin, Charles River, Global Payments, HubSpot, Insulet Corporation, Roper Technologies, Sabra Health Care, Western Digital, Zillow Group, and More
Wall Street analysts made some dramatic moves on Thursday, slashing price targets by double digits on several high-profile names while upgrading others to buy. Find out which stocks got the most…
-
2 months ago benzinga.com
Stifel Initiates Coverage On Lyell Immunopharma with Buy Rating, Announces Price Target of $36
Stifel analyst Stephen Willey initiates coverage on Lyell Immunopharma (NASDAQ:LYEL) with a Buy rating and announces Price Target of $36.
-
3 months ago benzinga.com
B. Riley Securities Initiates Coverage On Lyell Immunopharma with Buy Rating, Announces Price Target of $44
B. Riley Securities analyst Yuan Zhi initiates coverage on Lyell Immunopharma (NASDAQ:LYEL) with a Buy rating and announces Price Target of $44.
3 months ago defenseworld.net
Lyell Immunopharma, Inc. (NASDAQ:LYEL) Receives $43.00 Consensus Price Target from Analysts
Lyell Immunopharma, Inc. (NASDAQ: LYEL - Get Free Report) has received an average rating of "Moderate Buy" from the seven ratings firms that are currently covering the firm, Marketbeat.com reports.…
3 months ago benzinga.com
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Seer (NASDAQ:SEER) shares rose 32.1% to $2.14 during Monday's pre-market session. The market value of their outstanding shares is at $89.0 million. Innovative Eyewear (NASDAQ:LUCY) stock rose…
4 months ago zacks.com
Wall Street Analysts Think Lyell Immunopharma (LYEL) Could Surge 176.02%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 176% in Lyell Immunopharma (LYEL). While the effectiveness of this highly sought-after metric is questionable,…
4 months ago globenewswire.com
Lyell Immunopharma Announces Participation in H.C. Wainwright 4th Annual Cell Therapy Virtual Conference
SOUTH SAN FRANCISCO, Calif., June 25, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor…
-
4 months ago benzinga.com
Citizens Reiterates Market Outperform on Lyell Immunopharma, Maintains $34 Price Target
Citizens analyst Reni J. Benjamin reiterates Lyell Immunopharma (NASDAQ:LYEL) with a Market Outperform and maintains $34 price target.
4 months ago seekingalpha.com
Lyell Immunopharma: Undervalued Ahead Of A Major CAR-T Inflection
Lyell Immunopharma (LYLE) offers asymmetric upside, with ronde-cel showing best-in-class durability and safety in relapsed/refractory LBCL. LYLE trades near cash value, with the market heavily…
-
4 months ago benzinga.com
Lyell Immunopharma Announces Data From Its Phase 1/2 Clinical Study Of Rondecabtagene Autoleucel In Participants With Relapsed Or Refractory Large B-cell Lymphoma Shows Manufacturing Success Rate Of 97%
Lyell Immunopharma, Inc. (NASDAQ:LYEL), a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor (CAR) T-cell therapies for patients with cancer, is announcing…
4 months ago globenewswire.com
Lyell Immunopharma Presents Updated Safety Data and Translational Insights for Rondecabtagene Autoleucel (Ronde-Cel) in Patients with Large B-Cell Lymphoma at European Hematology Association 2026 Congress
More than 100 patients treated with ronde-cel in 2L and 3L+ LBCL, with a manufacturing success rate of 97% No Grade ≥ 3 CRS and low rates of Grade ≥ 3 ICANS, supporting outpatient administration…
4 months ago seekingalpha.com
Lyell Immunopharma, Inc. (LYEL) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Lyell Immunopharma, Inc. (LYEL) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
-
4 months ago benzinga.com
HC Wainwright & Co. Reiterates Buy on Lyell Immunopharma, Maintains $45 Price Target
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Lyell Immunopharma (NASDAQ:LYEL) with a Buy and maintains $45 price target.
4 months ago benzinga.com
Lyell Immunopharma Issues Colorectal Cancer Drug Safety Update
on Lyell Immunopharma Inc. (NASDAQ: LYEL) stock is up on Monday as the company is providing an update on the safety profile of its LYL273 treatment in a Phase 1 clinical trial for relapsed or…
4 months ago benzinga.com
Lyell Immunopharma Issues Colorectal Cancer Drug Safety Update
Lyell Immunopharma reports improved safety data for LYL273 in metastatic colorectal cancer and advances study to Phase 1/2 design.
-
4 months ago benzinga.com
Lyell Immunopharma Issues LYL273 Safety Profile Update In Its Ongoing U.S. Phase 1 Clinical Trial In Patients With Relapsed Or Refractory Metastatic Colorectal Cancer
Gastrointestinal prophylaxis reduced Grade ≥ 2 diarrhea/colitis from 55% without prophylaxis to 10% with prophylaxisThe maximum tolerated dose has not yet been determinedNo difference is observed in…
4 months ago globenewswire.com
Lyell Immunopharma Provides Update on Safety Profile of LYL273 in Relapsed or Refractory Metastatic Colorectal Cancer and Amends Phase 1 Trial to Phase 1/2 Expansion
SOUTH SAN FRANCISCO, Calif., June 08, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor…
-
5 months ago benzinga.com
Lyell Immunopharma To Present Data From Its Current Phase 1/2 Clinical Study Of Rondecabtagene Autoleucel In Participants With Relapsed Or Refractory Large B-Cell Lymphoma At European Hematology Association 2026 Congress
Lyell Immunopharma, Inc. (NASDAQ:LYEL), a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor (CAR) T-cell therapies for patients with cancer, today…
5 months ago globenewswire.com
Lyell Immunopharma to Present Phase 1/2 Safety and Translational Data for Ronde-Cel in Large B-Cell Lymphoma at the European Hematology Association 2026 Congress
SOUTH SAN FRANCISCO, Calif., June 04, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor…
5 months ago zacks.com
Lyell Immunopharma (LYEL) Loses 39.7% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Lyell Immunopharma (LYEL) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings…
-
5 months ago benzinga.com
HC Wainwright & Co. Reiterates Buy on Lyell Immunopharma, Maintains $45 Price Target
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Lyell Immunopharma (NASDAQ:LYEL) with a Buy and maintains $45 price target.
5 months ago globenewswire.com
Lyell Immunopharma Announces Participation in Goldman Sachs 47th Annual Global Healthcare Conference 2026
SOUTH SAN FRANCISCO, Calif., June 01, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor…
5 months ago marketbeat.com
Lyell Immunopharma Targets 2027 FDA Filing as CAR-T Pipeline Advances
Lyell Immunopharma NASDAQ: LYEL President and CEO Lynn Seely outlined the company's clinical development priorities, regulatory strategy and manufacturing plans during a Stifel investor session…
5 months ago seekingalpha.com
Lyell Immunopharma, Inc. (LYEL) Presents at Stifel 2026 Targeted Oncology Virtual Forum Transcript
Lyell Immunopharma, Inc. (LYEL) Presents at Stifel 2026 Targeted Oncology Virtual Forum Transcript
5 months ago seekingalpha.com
Lyell Immunopharma, Inc. (LYEL) Presents at H.C. Wainwright 4th Annual BioConnect Investor Conference Transcript
Lyell Immunopharma, Inc. (LYEL) Presents at H.C. Wainwright 4th Annual BioConnect Investor Conference Transcript
-
6 months ago benzinga.com
Lyell Immunopharma Q1 EPS $(1.10) Beats $(2.19) Estimate, Sales $2.000K Miss $4.400K Estimate
Lyell Immunopharma (NASDAQ:LYEL) reported quarterly losses of $(1.10) per share which beat the analyst consensus estimate of $(2.19) by 49.77 percent. This is a 69.44 percent increase over losses of…
6 months ago benzinga.com
This Nike Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday
Wall Street analysts changed outlook on top stocks. See rating changes on NKE, SMPL, WSR, NTNX, and AES. Check analyst views before buying NKE.
6 months ago benzinga.com
This WhiteFiber Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Friday
Top Wall Street analysts changed outlook on top names. Initiations & upgrades noted. For full changes, see analyst ratings page.
10 months ago benzinga.com
12 Health Care Stocks Moving In Monday's Intraday Session
12 Health Care Stocks Moving In Monday's Intraday Session
10 months ago benzinga.com
This Eaton Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday
This Eaton Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday
-
11 months ago benzinga.com
12 Health Care Stocks Moving In Monday's After-Market Session
12 Health Care Stocks Moving In Monday's After-Market Session
1 year ago benzinga.com
This United Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings…
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Thursday's After-Market Session
12 Health Care Stocks Moving In Thursday's After-Market Session
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Thursday's Intraday Session
12 Health Care Stocks Moving In Thursday's Intraday Session
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Intraday Session
12 Health Care Stocks Moving In Wednesday's Intraday Session
-
2 years ago benzinga.com
Why Deckers Outdoor Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket
Why Deckers Outdoor Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket
-
2 years ago benzinga.com
ZIM Integrated Shipping Services Posts Upbeat Earnings, Joins fuboTV, Foghorn Therapeutics And Other Big Stocks Moving Higher On Monday
ZIM Integrated Shipping Services Posts Upbeat Earnings, Joins fuboTV, Foghorn Therapeutics And Other Big Stocks Moving Higher On Monday
-
2 years ago benzinga.com
12 Health Care Stocks Moving In Thursday's After-Market Session
12 Health Care Stocks Moving In Thursday's After-Market Session
-
2 years ago benzinga.com
Why Tilray Brands Shares Are Trading Lower By Around 22%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Shares of Tilray Brands, Inc. (NASDAQ: TLRY) fell sharply during Tuesday’s session after the company missed third-quarter estimates and said it no longer expects to generate positive adjusted free
-
2 years ago benzinga.com
BlackBerry, Nurix Therapeutics, Tesla And Other Big Stocks Moving Higher On Tuesday
U.S. stocks were lower, with the Dow Jones index falling over 200 points on Tuesday. Shares of BlackBerry Limited (NYSE: BB) rose sharply during Tuesday’s session.
-
2 years ago benzinga.com
Tesla, Spirit Airlines, New York Community Bancorp And Other Big Stocks Moving Lower On Monday
U.S. stocks were lower, with the Dow Jones index falling around 80 points on Monday.
-
2 years ago benzinga.com
Why Longboard Pharmaceuticals Shares Are Trading Higher By Around 200%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Shares of Longboard Pharmaceuticals, Inc.